Cardiovascular Effects of Incretin-Based Therapies.
作者： William B. White , William L. Baker
DOI: 10.1146/ANNUREV-MED-050214-013431
关键词:
摘要: The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important new classes of therapy for type 2 diabetes mellitus (T2DM). These agents prolong the action incretin hormones, GLP-1 glucose-dependent insulinotropic polypeptide (GIP), by inhibiting their breakdown. hormones improve glycemic control in T2DM increasing insulin secretion suppressing glucagon levels. cardiovascular (CV) effects therapies have been substantial interest since 2008, when US Food Drug Administration began to require that all undergo rigorous assessment CV safety through large-scale outcome trials. This article reviews most recent trials DPP-4 (SAVOR-TIMI 53, EXAMINE, TECOS) as evidence acceptable profiles patients with T2DM. studies differ regard patient population, trial duration, heart failure outcomes but show similar findings death, nonfatal myocardial infarction, stroke, well hospitalization unstable angina.
sci-hub.se 参考文章(77)
Juris J. Meier, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. ,vol. 8, pp. 728- 742 ,(2012) , 10.1038/NRENDO.2012.140
Nelson Gomez, Karim Touihri, Veerle Matheeussen, Agnès Mendes Da Costa, Maryam Mahmoudabady, Myrielle Mathieu, Lesley Baerts, Aaron Peace, Pascale Lybaert, Simon Scharpé, Ingrid De Meester, Jozef Bartunek, Marc Vanderheyden, Kathleen McEntee, Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. European Journal of Heart Failure. ,vol. 14, pp. 14- 21 ,(2012) , 10.1093/EURJHF/HFR146
John R Ussher, Daniel J Drucker, None, Cardiovascular Biology of the Incretin System Endocrine Reviews. ,vol. 33, pp. 187- 215 ,(2012) , 10.1210/ER.2011-1052
Masakazu Ishii, Rei Shibata, Kazuhisa Kondo, Takahiro Kambara, Yuuki Shimizu, Tohru Tanigawa, Yasuko K. Bando, Masahiro Nishimura, Noriyuki Ouchi, Toyoaki Murohara, Vildagliptin Stimulates Endothelial Cell Network Formation and Ischemia-induced Revascularization via an Endothelial Nitric-oxide Synthase-dependent Mechanism Journal of Biological Chemistry. ,vol. 289, pp. 27235- 27245 ,(2014) , 10.1074/JBC.M114.557835
Renee E. Amori, Joseph Lau, Anastassios G. Pittas, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. ,vol. 298, pp. 194- 206 ,(2007) , 10.1001/JAMA.298.2.194
Steven E. Nissen, Cardiovascular Effects of Diabetes Drugs: Emerging From the Dark Ages Annals of Internal Medicine. ,vol. 157, pp. 671- 672 ,(2012) , 10.7326/0003-4819-157-9-201211060-00016
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B. Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen, Lene Holmvang, Leif Thuesen, Lars Romer Krusell, Jan S. Jensen, Lars Køber, Marek Treiman, Jens Juul Holst, Thomas Engstrøm, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction European Heart Journal. ,vol. 33, pp. 1491- 1499 ,(2012) , 10.1093/EURHEARTJ/EHR309
Veerle Matheeussen, Lesley Baerts, Guido De Meyer, Gilles De Keulenaer, Pieter Van der Veken, Koen Augustyns, Véronique Dubois, Simon Scharpé, Ingrid De Meester, Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biological Chemistry. ,vol. 392, pp. 189- 198 ,(2011) , 10.1515/BC.2011.002
Jens Kristensen, Ulrik M Mortensen, Morten Schmidt, Peter Haubjerg Nielsen, Torsten Toftegaard Nielsen, Michael Maeng, Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovascular Disorders. ,vol. 9, pp. 31- 31 ,(2009) , 10.1186/1471-2261-9-31
R. E. Pratley, C. Weyer, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. ,vol. 44, pp. 929- 945 ,(2001) , 10.1007/S001250100580